Long-term Follow-up and Role of FDG PET in Advanced Pancreatic Neuroendocrine Patients Treated with Lu-D OTATATE

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2016 Oct 6

PMID 27704193

Citations 55

Authors

Maddalena Sansovini

Stefano Severi

Annarita Ianniello

Silvia Nicolini

Lorenzo Fantini

Emilio Mezzenga

Fabio Ferroni

Emanuela Scarpi

Manuela Monti

Alberto Bongiovanni

Sara Cingarlini

Chiara Maria Grana

Lisa Bodei

Giovanni Paganelli

Affiliations

Soon will be listed here.

Abstract

Purpose: Lu-DOTATATE (Lu-PRRT) is a valid therapeutic option in differentiated pancreatic neuroendocrine tumors (P-NETs). FDG PET seems to be an important prognostic factor in P-NETs. We evaluated the efficacy of Lu-PRRT and the role of FDG PET in 60 patients with advanced P-NETs.

Methods: From March 2008 to June 2011, 60 consecutive patients with P-NETs were enrolled in the study. Follow-up lasted until March 2016. Eligible patients were treated with two different total cumulative activities (18.5 or 27.8 GBq in 5 cycles every 6-8 weeks), according to kidney and bone marrow parameters.

Results: Twenty-eight patients received a mean full activity (FA) of 25.9 GBq and 32 a mean reduced activity (RA) of 18.5 GBq. The disease control rate (DCR), defined as the sum of CR+PR+SD was 85.7 % in the FA group and 78.1 % in the RA group. Median progression-free survival (mPFS) was 53.4 months in the FA group and 21.7 months in the RA group (P = 0.353). Median overall survival (mOS) was not reached (nr) in FA patients and was 63.8 months in the RA group (P = 0.007). Fifty-five patients underwent an FDG PET scan before Lu-PRRT, 32 (58 %) showing an increased FDG uptake in tumor sites. mPFS was 21.1 months in FDG PET-positive patients and 68.7 months in the FDG PET-negative group (P < 0.0002), regardless of the total activity administered.

Conclusion: Both FA and RA are active in patients undergoing Lu-PRRT. However, an FA of 27.8 GBq of Lu-PRRT prolongs PFS and OS compared to an RA of 18.5 GBq. Our results indicate that FDG PET is an independent prognostic factor in this patient setting.

Citing Articles

The Safety and Efficacy of Peptide Receptor Radionuclide Therapy for Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Single Center Experience.

Piscopo L, Zampella E, Volpe F, Gaudieri V, Nappi C, Di Donna E Curr Oncol. 2024; 31(9):5617-5629.

PMID: 39330044 PMC: 11431754. DOI: 10.3390/curroncol31090416.

Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study.

Partelli S, Landoni L, Bartolomei M, Zerbi A, Grana C, Boggi U Br J Surg. 2024; 111(9).

PMID: 39213395 PMC: 11364141. DOI: 10.1093/bjs/znae178.

Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.

Di Franco M, Zanoni L, Fortunati E, Fanti S, Ambrosini V Curr Oncol Rep. 2024; 26(5):538-550.

PMID: 38581469 PMC: 11063107. DOI: 10.1007/s11912-024-01526-5.

Resistant gastroenteropancreatic neuroendocrine tumors: a definition and guideline to medical and surgical management.

Davis C, Laird A, Libutti S Proc (Bayl Univ Med Cent). 2024; 37(1):104-110.

PMID: 38174011 PMC: 10761146. DOI: 10.1080/08998280.2023.2284039.

Diagnostic and prognostic value of Tc-Tektrotyd scintigraphy and F-FDG PET/CT in a single-center cohort of neuroendocrine tumors.

Saponjski J, Macut D, Petrovic N, Ognjanovic S, Popovic B, Bukumiric Z Arch Med Sci. 2023; 19(6):1753-1759.

PMID: 38058718 PMC: 10696987. DOI: 10.5114/aoms/130996.

References

Kim S, Pak K, Koo P, Kwak J, Chang S . The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015; 42(13):1964-70. DOI: 10.1007/s00259-015-3155-x. View

Kashyap R, Hofman M, Michael M, Kong G, Akhurst T, Eu P . Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014; 42(2):176-85. DOI: 10.1007/s00259-014-2906-4. View

Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A . 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010; 16(3):978-85. DOI: 10.1158/1078-0432.CCR-09-1759. View

Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard A, Bouriel C . Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009; 50(6):858-64. DOI: 10.2967/jnumed.108.057505. View

Pfeifer A, Gregersen T, Gronbaek H, Hansen C, Muller-Brand J, Bruun K . Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology. 2011; 93(3):189-96. DOI: 10.1159/000324096. View

Tang L, Gonen M, Hedvat C, Modlin I, Klimstra D . Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol. 2012; 36(12):1761-70. DOI: 10.1097/PAS.0b013e318263207c. View

Gupta S, Singla S, Bal C . Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE. Cancer Biother Radiopharm. 2012; 27(9):593-9. DOI: 10.1089/cbr.2012.1195. View

Modlin I, Oberg K, Taylor A, Drozdov I, Bodei L, Kidd M . Neuroendocrine tumor biomarkers: current status and perspectives. Neuroendocrinology. 2014; 100(4):265-77. DOI: 10.1159/000368363. View

Sansovini M, Severi S, Ambrosetti A, Monti M, Nanni O, Sarnelli A . Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. Neuroendocrinology. 2013; 97(4):347-54. DOI: 10.1159/000348394. View

10.

Sandstrom M, Garske-Roman U, Granberg D, Johansson S, Widstrom C, Eriksson B . Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2012; 54(1):33-41. DOI: 10.2967/jnumed.112.107524. View

11.

Kwekkeboom D, de Herder W, Kam B, Van Eijck C, Van Essen M, Kooij P . Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13):2124-30. DOI: 10.1200/JCO.2007.15.2553. View

12.

Severi S, Nanni O, Bodei L, Sansovini M, Ianniello A, Nicoletti S . Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013; 40(6):881-8. DOI: 10.1007/s00259-013-2369-z. View

13.

Kesavan M, Claringbold P, Turner J . Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up. Neuroendocrinology. 2014; 99(2):108-17. DOI: 10.1159/000362558. View

14.

Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A . Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014; 41(5):925-33. DOI: 10.1007/s00259-013-2677-3. View

15.

Ngo H, Tortorella S, Ververis K, Karagiannis T . The Warburg effect: molecular aspects and therapeutic possibilities. Mol Biol Rep. 2014; 42(4):825-34. DOI: 10.1007/s11033-014-3764-7. View

16.

Delpassand E, Samarghandi A, Zamanian S, Wolin E, Hamiditabar M, Espenan G . Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014; 43(4):518-25. DOI: 10.1097/MPA.0000000000000113. View

17.

Paganelli G, Sansovini M, Ambrosetti A, Severi S, Monti M, Scarpi E . 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging. 2014; 41(10):1845-51. DOI: 10.1007/s00259-014-2735-5. View

18.

Bergsma H, Konijnenberg M, Kam B, Teunissen J, Kooij P, de Herder W . Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course. Eur J Nucl Med Mol Imaging. 2015; 43(3):453-63. PMC: 4731438. DOI: 10.1007/s00259-015-3193-4. View

19.

Lawrence B, Gustafsson B, Chan A, Svejda B, Kidd M, Modlin I . The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011; 40(1):1-18, vii. DOI: 10.1016/j.ecl.2010.12.005. View

20.

Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul J . High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J Nucl Med. 2014; 55(11):1786-90. DOI: 10.2967/jnumed.114.144386. View